Cellarity, a Somerville, MA-based life sciences company, raised $121M in Series C funding.
The round, which brought total funding raised to date to $274m, was led by Flagship Pioneering with participation from Kyowa Kirin and Hanwha Impact Partners.
The company intends to use the funds to grow its talent base, strengthen its platform, and advance its pipeline toward the clinic.
Led by CEO Fabrice Chouraqui, Cellarity has developed capabilities combining high-resolution data, single-cell technologies, and machine learning to investigate complex disease biology and purposefully design breakthrough medicines.
To create medicines, the company looks beyond individual molecular targets and instead focuses on the whole cell. It uses single-cell technologies to identify cellular drivers during the transition from health to disease and applies proprietary deep learning models to create drugs that reverse disease at the level of the cell. Cellarity has developed capabilities to link biology and chemistry with high dimensional, transcriptomic data to design medicines against the cellular signature of the disease. The platform provides critical insights into cellular dysfunction and reveals new biology through which we can address a range of diseases, including those which presently lack a known druggable target.
FinSMEs
04/10/2022